SCHEMBL24317747

SCHEMBL24317747

CCOC(=O)c1cccc(Cc2ccc3c4c(cccc24)NC3=O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 1/20 0.45
CYP4A11 Q02928 1/20 0.45
CCNB2 O95067 1/20 0.43
CDK1 P06493 1/20 0.43
CCNB1 P14635 1/20 0.43
MDH2 P40926 1/20 0.43
CCNB3 Q8WWL7 1/20 0.43
MEP1B Q16820 1/20 0.43
MAPT P10636 5/20 0.42
KDM4E B2RXH2 3/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 2/20 0.42
MAPK1 P28482 2/20 0.42
USP2 O75604 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
ALDH1A1 P00352 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24317388 0.89 RXFP1 (0.43) CCNB2CDK1CCNB1MDH2CCNB3
SCHEMBL24317445 0.84 PDE3B (0.42) MAPTKDM4EHPGDHSD17B10MAPK1
SCHEMBL11317546 0.77 KDM4E (0.47) MAPTKDM4EHPGDHSD17B10MAPK1
SCHEMBL24317881 0.76 MAPT (0.53) MAPTKDM4EHPGDHSD17B10LMNA
SCHEMBL24317629 0.73 MAOB (0.43) MAPTKDM4EHPGDHSD17B10HTT
SCHEMBL29532220 0.73 CRBN (0.46) MAPK1TSHRALDH1A1
SCHEMBL11322480 0.73 KDM4E (0.53) MAPTKDM4EHPGDHSD17B10MAPK1
SCHEMBL9749072 0.71 CDC25B (0.53) CYP4F2CYP4A11CDC25B
SCHEMBL24317439 0.70 PARP1 (0.41) KDM4EHPGDHSD17B10USP2ALOX15
SCHEMBL24317645 0.70 MAPT (0.48) MAPTKDM4EHPGDHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C 4 Therapeutics, Inc. (US) 2024-01-18 US disclosed
WO-2022081927-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY C4 THERAPEUTICS, INC. (US) 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018118-A1 TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY NFATC1, CTSS, MMP12 CYP4F2 3435/4885CYP4A11 1472/4885CCNB2 610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.